THE SPECIFICS OF PRESCRIBING TRIPLE ANTITROMBOTIC THERAPY WITH RIVAROXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AFTER CORONARY ARTERY STENTING
A trial fibrillation occurs in 5 to 8% of patients who underwent percutaneous coronary intervention (PCI) with stenting. It is known that dual antiplatelet therapy (a combination of P2Y12 receptor inhibitor and acetylsalicylic acid) significantly reduces the risk of developing stent thrombosis in co...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«REMEDIUM GROUP» Ltd.
2017-05-01
|
| Series: | Атеротромбоз |
| Subjects: | |
| Online Access: | https://www.aterotromboz.ru/jour/article/view/114 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850182151278952448 |
|---|---|
| author | N. A. Novikova A. S. Shilova |
| author_facet | N. A. Novikova A. S. Shilova |
| author_sort | N. A. Novikova |
| collection | DOAJ |
| description | A trial fibrillation occurs in 5 to 8% of patients who underwent percutaneous coronary intervention (PCI) with stenting. It is known that dual antiplatelet therapy (a combination of P2Y12 receptor inhibitor and acetylsalicylic acid) significantly reduces the risk of developing stent thrombosis in comparison with vitamin K antagonists; however, anticoagulants are significantly more effective in reducing the risk of ischemic stroke in patients with atrial fibrillation (AF). When opting for a long-term triple antithrombotic therapy, the risk of hemorrhagic complications increases dramatically, while choosing less intensive treatment results in an increased risk of ischemic complications, primarily, ischemic stroke and stent thrombosis. The current recommendations come down to the prescription of all of the three components of antithrombotic therapy. However, this approach leads to a significant increase in the frequency of hemorrhagic complications. The purpose of recent randomized trials was to compare and evaluate the efficacy and safety of different regimens with antithrombotic drugs in combination with rivaroxaban in patients with AF who underwent PCI. |
| format | Article |
| id | doaj-art-7c6771cd07894b33a59a7fa138a9f8e5 |
| institution | OA Journals |
| issn | 2307-1109 2658-5952 |
| language | Russian |
| publishDate | 2017-05-01 |
| publisher | «REMEDIUM GROUP» Ltd. |
| record_format | Article |
| series | Атеротромбоз |
| spelling | doaj-art-7c6771cd07894b33a59a7fa138a9f8e52025-08-20T02:17:41Zrus«REMEDIUM GROUP» Ltd.Атеротромбоз2307-11092658-59522017-05-010111412110.21518/2307-1109-2017-1-114-121108THE SPECIFICS OF PRESCRIBING TRIPLE ANTITROMBOTIC THERAPY WITH RIVAROXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AFTER CORONARY ARTERY STENTINGN. A. Novikova0A. S. Shilova1First Moscow State Medical University named after I.M. SechenovFirst Moscow State Medical University named after I.M. SechenovA trial fibrillation occurs in 5 to 8% of patients who underwent percutaneous coronary intervention (PCI) with stenting. It is known that dual antiplatelet therapy (a combination of P2Y12 receptor inhibitor and acetylsalicylic acid) significantly reduces the risk of developing stent thrombosis in comparison with vitamin K antagonists; however, anticoagulants are significantly more effective in reducing the risk of ischemic stroke in patients with atrial fibrillation (AF). When opting for a long-term triple antithrombotic therapy, the risk of hemorrhagic complications increases dramatically, while choosing less intensive treatment results in an increased risk of ischemic complications, primarily, ischemic stroke and stent thrombosis. The current recommendations come down to the prescription of all of the three components of antithrombotic therapy. However, this approach leads to a significant increase in the frequency of hemorrhagic complications. The purpose of recent randomized trials was to compare and evaluate the efficacy and safety of different regimens with antithrombotic drugs in combination with rivaroxaban in patients with AF who underwent PCI.https://www.aterotromboz.ru/jour/article/view/114rivaroxabantriple antithrombotic therapyatrial fibrillationpercutaneous coronary interventionhemorrhagic complications |
| spellingShingle | N. A. Novikova A. S. Shilova THE SPECIFICS OF PRESCRIBING TRIPLE ANTITROMBOTIC THERAPY WITH RIVAROXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AFTER CORONARY ARTERY STENTING Атеротромбоз rivaroxaban triple antithrombotic therapy atrial fibrillation percutaneous coronary intervention hemorrhagic complications |
| title | THE SPECIFICS OF PRESCRIBING TRIPLE ANTITROMBOTIC THERAPY WITH RIVAROXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AFTER CORONARY ARTERY STENTING |
| title_full | THE SPECIFICS OF PRESCRIBING TRIPLE ANTITROMBOTIC THERAPY WITH RIVAROXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AFTER CORONARY ARTERY STENTING |
| title_fullStr | THE SPECIFICS OF PRESCRIBING TRIPLE ANTITROMBOTIC THERAPY WITH RIVAROXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AFTER CORONARY ARTERY STENTING |
| title_full_unstemmed | THE SPECIFICS OF PRESCRIBING TRIPLE ANTITROMBOTIC THERAPY WITH RIVAROXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AFTER CORONARY ARTERY STENTING |
| title_short | THE SPECIFICS OF PRESCRIBING TRIPLE ANTITROMBOTIC THERAPY WITH RIVAROXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AFTER CORONARY ARTERY STENTING |
| title_sort | specifics of prescribing triple antitrombotic therapy with rivaroxaban in patients with atrial fibrillation after coronary artery stenting |
| topic | rivaroxaban triple antithrombotic therapy atrial fibrillation percutaneous coronary intervention hemorrhagic complications |
| url | https://www.aterotromboz.ru/jour/article/view/114 |
| work_keys_str_mv | AT nanovikova thespecificsofprescribingtripleantitrombotictherapywithrivaroxabaninpatientswithatrialfibrillationaftercoronaryarterystenting AT asshilova thespecificsofprescribingtripleantitrombotictherapywithrivaroxabaninpatientswithatrialfibrillationaftercoronaryarterystenting AT nanovikova specificsofprescribingtripleantitrombotictherapywithrivaroxabaninpatientswithatrialfibrillationaftercoronaryarterystenting AT asshilova specificsofprescribingtripleantitrombotictherapywithrivaroxabaninpatientswithatrialfibrillationaftercoronaryarterystenting |